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Apabetalone (RVX-208) inhibits the interaction between epige-
netic regulators known as bromodomain and extraterminal (BET)
proteins and acetyl-lysine marks on histone tails. Data presented
here supports the manuscript published in Atherosclerosis “RVX-
208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Dis-
ease, Raises ApoA-I/HDL and Represses Pathways that Contribute to
Cardiovascular Disease” (Gilham et al., 2016) [1]. It shows that RVX-
208 and a comparator BET inhibitor (BETi) JQ1 increase mRNA
expression and production of apolipoprotein A-I (ApoA-I), the
main protein component of high density lipoproteins, in primary
human and African green monkey hepatocytes. In addition,
reported here are gene expression changes from a microarray-
based analysis of human whole blood and of primary human
hepatocytes treated with RVX-208.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.atherosclerosis.2016.01.036
lgary, Canada.
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Fig. 1. Effect of RVX-208 on
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RVX-208 for 48 h (B). Data a
npo0.05 versus DMSO treaubject area Molecular biology
ore speciﬁc sub-
ject areaAtherosclerosisype of data Graphs and tables
ow data was
acquiredReal-time PCR using TaqMan assays; ELISA; Microarray analysis using Affyme-
trix Human Genome U133 Plus 2.0 and 2.4 Arrays.ata format Analyzed
xperimental
factorsin vitro treatment of cultured primary cells with RVX-208, JQ1 or DMSO for up to
72 h.xperimental
featuresmRNA and media were collected from cultured primary hepatocytes and ana-
lyzed by real-time PCR and ELISA, respectively. Human whole blood from healthy
volunteers was treated ex vivo with BET inhibitors. Total RNA was extracted from
treated whole blood and hepatocytes and analyzed using gene microarrays.ata source
location51.010467°N, -114.123538°Wata accessibility Data is supplied with this article.D
Value of the data
 Data demonstrate suitability of human and African green monkey primary hepatocyte 3D culture
systems for expression studies of the ApoA-I gene and protein.
 Data demonstrate suitability of a recently developed anti-proApoA-I antibody to measure newly
produced ApoA-I protein in human primary hepatocytes.
 The gene expression data from human whole blood and primary hepatocytes reported here pro-
vide an RVX-208 transcriptional signature that can be compared to other compounds targeting BET
proteins.1. Data
Data presented here supports the manuscript published in Atherosclerosis “RVX-208, a BET-
inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL and Represses
Pathways that Contribute to Cardiovascular Disease” (Gilham et al., 2016) [1].ApoA-I mRNA expression in African green monkey hepatocytes. Hepatocyte 3-D cultures supplied
CA) were treated with 30 mM RVX-208 over a time course (A) or the indicated concentrations of
re the mean from independent triplicate samples, while error bars represent standard deviation.
ted samples at the same time point using two-tailed Student's t-tests.
Fig. 2. Comparison of effects of RVX-208 and JQ1 on ApoA-I protein secretion from cryopreserved primary human hepatocytes.
Secreted total ApoA-I and proApoA-I protein levels were determined by ELISA in spent media from cells treated with 0.1%
DMSO, 30 mM RVX-208 or 0.6 mM JQ1 for 72 h.
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RVX-208 treatment was assessed in primary hepatocytes from African green monkey grown in a 3-D
culture system (Fig. 1). In primary human hepatocytes, the effect of RVX-208 on newly synthesized
ApoA-I protein was compared to that of JQ1, a BETi with a distinct chemical scaffold (Fig. 2). Changes
in expression of genes involved in inﬂammation and atherosclerosis [2–79] were identiﬁed by
microarrays from human whole blood and human primary hepatocytes treated in vitro with RVX-208
(Tables 1–5).2. Experimental design, materials and methods
2.1. Detection of ApoA-I mRNA in primary hepatocytes from African green monkey
Primary hepatocytes from African green monkey were supplied by RegeneMed Inc. (San Diego,
CA). Stromal cells were grown concurrently on a nylon mesh scaffold with fresh liver parenchymal
cells to create a three dimensional culture. Cells were treated with 0.1% DMSO or RVX-208 for 3 h,
24 h or 48 h, mRNA was puriﬁed with mRNA CatcherTM PLUS kits (Life Technologies) and mRNA
expression analysis was performed by TaqMans based real-time PCR as described previously [80].
2.2. Detection of ApoA-I mRNA in primary human hepatocytes
Primary human hepatocytes (CellzDirect/Life Technologies) were plated as recommended by the
supplier. Cells were treated with 0.1% DMSO, 30 mM RVX-208 or 0.6 mM JQ1 for 48 h, mRNA was
puriﬁed and mRNA expression analyzed as above.
2.3. Detection of ApoA-I and proApoA-I secreted by primary human hepatocytes
Primary human hepatocytes (CellzDirect/Life Technologies) were treated with 0.1% DMSO, 30 mM
RVX-208 or 0.6 mM JQ1 for 72 h and media samples containing secreted proteins were analyzed by
ELISA. A rabbit monoclonal anti-proApoA-I antibody was generated using a synthetic peptide
RHFWQQ_DEPP [1]. The antibody was used to coat EIA/RIA high binding surface microplates (Corn-
ing) overnight. Plates were washed, and then blocked with 5% skim milk. Recombinant poly-histidine
tagged human proApoA-I (Genscript, Piscataway, NJ) was used as a standard. Recombinant protein or
media samples with were introduced onto plates, incubated with anti-human ApoA-I (Calbiochem #
178470), and then with HRP conjugated anti-mouse IgG (Calbiochem # 401253). Color was developed
by treatment with tetramethylbenzidine, followed by sulfuric acid. Plates were read on a Thermo
Scientiﬁc Multiskan GO Spectrophotometer at 450 nm. ApoA-I ELISA was performed in a similar
Table 1
The effect of RVX-208 on expression of pro-atherogenic genes in human whole blood treated ex vivo for 24 h.
Gene
symbol
Fold
change
Effects on atherosclerotic processes in vitro and in vivo Ref.
CCL18 7.0 pro-inﬂammatory cytokine; ↑ sites of occlusion during AMI [4]
SPP1 6.5 ↓ atherosclerosis in SPP1/ApoE DKO with ANGII infusion; ↑ sites of occlusion during AMI [4,5]
CCL23 5.8 mediates chemotaxis, expression of adhesion molecule and MMP-2 release from
monocytes
[6]
PIK3R3 5.1 PIK3R3 inhibitor ↓ atherosclerosis in ApoE KO; ↓ atherosclerosis in PIK3R3/LDLR DKO [7,8]
FCGR1A 4.8 ↓ atherosclerosis in FCGR1A/ApoE DKO [9]
ITGA9 4.6 enhances macrophage chemotaxis, receptor for SPP1 [10]
IL2RA 4.1 mAb against IL-2 ↓ atherosclerosis in ApoE KO; IL-2 stimulates T cells, but also expands Treg
cells (atheroprotective)
[11]
F13A1 3.6 factor XIIIA inhibitor ↓ atherosclerosis in ApoE KO [12]
PROK2 3.4 pro-inﬂammatory; overexpressed at sites of aneurysm rupture [13]
CXCL1 3.2 ↓ atherosclerosis in CXCL1/LDLR DKO [14]
GHRL 3.0 enhances monocyte adhesion and oxidized low-density lipoprotein binding [15]
ANGPT1 3.0 promotes monocyte and neutrophil migration and activates smooth muscle cells [16]
LPL 2.9 ↓ atherosclerosis in LPL KO (BMT)/LDLR KO [17]
IL26 2.8 pro-inﬂammatory cytokine produced by Th17 cells [18]
C3 2.5 ↑ inﬂammation, destabilizes plaque; deﬁciency ↑atherogenesis in LDLR KO [19,20]
IL23A 2.0 cytokine, elevated in patients with peripheral arterial disease; role in advanced athero-
sclerotic plaque progression
[21,22]
VEGFA 2.0 ↑ atherosclerosis in ApoE KO upon injection of recombinant VEGF [23]
TLR2 1.8 ↓ atherosclerosis in TLR2/LDLR DKO [24]
TNFSF13 1.8 enhanced expression in atherosclerotic disorders [25]
IL12RB1 1.7 receptor for IL23A and IL12; mediates pro-inﬂammatory signaling [26,27]
TNFRSF8 1.7 mediates activation and proliferation of T and B cells; altered TNFRSF8 function ↓ ather-
osclerosis in ApoE KO
[28]
NFAT5 1.7 ↓ atherosclerosis in NFAT5/apoE DKO and NFAT KO (BMT)/apoE KO [29]
PIK3R2 1.5 PI3K signaling promotes foam cell formation [7,8]
IL12B 1.3 IL-12 induces T-cell recruitment into atherosclerotic plaque [27]
OSMR 1.3 monocyte- and T-cell-speciﬁc cytokine; promotes VSMC proliferation, migration and ECM
protein synthesis
[30]
IL8 1.3 pro-inﬂammatory cytokine; associated with AMI risk [31]
AKR1B1 1.4 ↑ atherosclerosis in AKR1B1 Tg/LDLR KO (diabetic) [32]
PIK3R1 1.5 PI3K signaling promotes foam cell formation [7,8]
LTA 1.8 ↓ atherosclerosis in LTA/ApoE DKO [33]
IRAK4 1.8 ↓ atherosclerosis in IRAK4 inactive knockin in ApoE KO plus carotid ligation [34]
C5 3.0 ↑ inﬂammation, destabilizes plaque; ↑ atherosclerosis in C5/ApoE DKO [35,36]
ADRB1 3.6 inhibitors attenuate atherosclerosis in ApoE KO [37]
AMI: acute myocardial infarction; ANGII: angiotensin II; BMT: bone marrow transplant; DKO: double knockout; ECM: extra-
cellular matrix; KO: knockout; mAb: monoclonal antibody; Tg: transgene; Treg: regulatory T-cells; VSMC: vascular smooth
muscle cells; Italics indicates literature support for both pro-and anti-atherosclerotic roles. Fold change indicates changes in
gene expression relative to 1 in vehicle-treated samples. For all entries, po0.05 versus DMSO treated samples in a two-tailed
Student's t-test.
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The standard was puriﬁed ApoA-I (Calbiochem # 178452) and it was detected using a polyclonal
rabbit anti-human ApoA-I antibody (Calbiochem # 178422), followed by HRP conjugated anti-rabbit
IgG (Calbiochem # 401353).
2.4. Gene expression microarray from human whole blood
After obtaining informed consent, whole blood was collected from three healthy volunteers into
BD Vacutainer Sodium Heparin tubes (# 367874 ) and samples were inverted 10 times. Blood samples
(1 mL) were combined with 1 mL of RPMI containing 2 mM glutamine, 1% penicillin/streptomycin,
20% FBS and 20 mM RVX-208 or vehicle (0.1% DMSO), followed by a 3 h or 24 h incubation at 37 °C in a
tissue culture incubator (CO2 at 5.5% concentration). Treated samples were transferred to PAXgene
Table 2
The effect of RVX-208 on expression of pro-atherogenic genes in human whole blood treated ex vivo for 3 h.
Gene
symbol
Fold
change
Effects on atherosclerotic processes in vitro and in vivo Ref.
FN1 21.0 FN1 promotes thrombogenesis and atherogenesis; ↑ sites of occlusion during AMI [4,38–
40]
CCL2 8.2 promotes chemotaxis in monocytes and basophils; binds to CCR2 and CCR4; ↑ sites of
occlusion during AMI
[4,41]
CCL8 6.1 Promotes chemotaxis in monocytes, lymphocytes, basophils and eosinophils [41]
CCL7 4.8 promotes chemotaxis in monocytes and basophils; binds to chemokine receptors CCR1,
CCR2, CCR3
[42]
SPP1 3.1 ↓ atherosclerosis SPP1/ApoE DKO with ANGII infusion; ↑ sites of occlusion during AMI [4,5]
ANGPT1 3.1 promotes monocyte and neutrophil migration; activates VSMC [16]
THBS1 2.9 Pro- and anti-atherogenic activities [43]
CXCL2 2.7 chemokine involved in monocyte recruitment to the endothelium [44,45]
CXCL3 2.5 chemokine involved in monocyte recruitment to the endothelium [45]
CXCL1 2.4 pro-inﬂammatory; promotes chemotaxis in neutrophils. [45,46]
CCR2 2.4 chemokine receptor involved in monocyte recruitment; induces VSMC [42,47]
DDR1 2.3 ↓ atherosclerosis in DDR1/LDLR DKO [48,49]
ANGPTL3 1.6 ↓ atherosclerosis in ANGPTL3hypl/ApoE KO [50]
ADORA2A 1.5 ↓ atherosclerosis in ADORA2A KO (BMT)/ApoE KO [51]
IL8 1.4 pro-inﬂammatory cytokine; associated with AMI risk [31]
CTSK 2.6 ↓ atherosclerosis in CatK/ApoE DKO; stabilizes plaque [52]
TNFSF4 3.2 ↓ atherosclerosis in ApoE/TNFSF4 DKO or ApoE KOþanti-TNFSF4 (MGP34) antibody-fed
mice
[53]
ROCK2 3.3 ↓ atherosclerosis in ROCK2 KO (BMT)/ApoE KO [54]
AMI: acute myocardial infarction; ANGII: angiotensin II; BMT: bone marrow transplant; DKO: double knockout; ECM: extra-
cellular matrix; hypl: recessive mutation; KO: knockout; mAb: monoclonal antibody; Tg: transgene; Treg: regulatory T-cells;
VSMC: vascular smooth muscle cells. Italics indicates literature support for both pro-and anti-atherosclerotic roles. Fold change
indicates changes in gene expression relative to 1 in vehicle-treated samples. For all entries, po0.05 versus DMSO treated
samples in a two-tailed Student's t-test.
Table 3
The effect of RVX-208 on expression of anti-atherogenic genes in human whole blood treated ex vivo for 24 h.
Gene
symbol
Fold
change
Effects on atherosclerotic processes in vitro and in vivo Ref.
EDIL3 3.3 regulates leukocyte-endothelial adhesion [55]
IGF1 2.3 ↓ atherosclerosis in IGF1/ApoE DKO [56,57]
ADIPOQ 2.0 ↓ atherosclerosis in ADIPOQ OE/ApoE KO [58]
ACVRL1 1.8 Expressed in vascular endothelial cells and monocytes. Activation protects against
atherosclerosis.
[59,60]
COL18A1 1.8 ↓ atherosclerosis in endostatin (COL18A1 fragment)-fed ApoE KO [61]
ACE2 1.3 ↑ atherosclerosis in ACE2-/y ApoE DKO and in ACE2-/y LDLR DKO [62,63]
TGFB1 1.4 ↓ atherosclerosis and stabilizes plaques in TGFB1-overexpressing ApoE KO [64]
TIMP1 1.6 ↓ atherosclerosis and ↑ plaque stability in TIMP2 OE/ApoE KO; medial lamina ruptures in
TIMP1-/y/ApoE DKO
[65,66]
MERTK 1.6 ↑ atherosclerosis in MERTK KO (BMT)/LDLR KO [67,68]
NR3C1 1.8 ↓ vascular calciﬁcation without affecting atherosclerotic lesion in macrophage-speciﬁc
NR3C1 KO (BMT)/LDLR KO
[69]
CDKN2A 1.9 ↑ atherosclerosis in CDKN2A/ApoE DKO and in CDKN2A KO (BMT)/LDLR KO [70,71]
CXCR5 2.3 anti-inﬂammatory effects through monocyte signaling [72]
BMT: bone marrow transplant; DKO: double knockout; KO: knockout; OE: overexpression; -/y : X-linked gene, 100% KO in
males fold change indicates changes in gene expression relative to 1 in vehicle-treated samples. For all entries, po0.05 versus
DMSO treated samples in a two-tailed Student's t-test.
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RNA kit according to the manufacturer's instructions. Microarrays were performed by Asuragen Inc.
Table 4
Effect of RVX-208 on expression of anti-atherogenic genes in human whole blood treated ex vivo for 3 h.
Gene
symbol
Fold
change
Effects on atherosclerotic processes
in vitro and in vivo
Ref.
IKBKB 1.5 ↑ atherosclerosis IKBKB KO (macrophage-
speciﬁc)/ApoE KO
[73]
LIPA 1.5 ↓ atherosclerosis in LIPA-fed LDLRKO [74]
IRF8 1.3 ↑ atherosclerosis in IRF8/ApoE DKO [75]
NR1H4 1.3 ↓ atherosclerosis in synthetic ligand-fed ApoE
KO; ↓ atherosclerosis in NR1H4/ApoE DKO
[76,77]
ABCA1 1.5 ↑ atherosclerosis in ABCA1/ApoE DKO [78]
CXCL13 2.3 stabilizes plaque through CXCL13-CXCR5
interaction
[44,79]
BMT: bone marrow transplant; DKO: double knockout; KO: knockout. Italics indicates literature support for both pro-and anti-
atherosclerotic roles; fold change indicates changes in gene expression relative to 1 in vehicle-treated samples. For all entries,
po0.05 versus DMSO treated samples in a two-tailed Student's t-test.
Table 5
Genes that encode acute phase response proteins associated with HDL are modulated by RVX-208 in primary human hepa-
tocytes. Gene expression changes measured in primary human hepatocytes treated with 30 mM RVX-208 for 48 h are expressed
as fold change versus DMSO treated cells. For all values, po0.05 as determined by a two-tailed Student's t-test.
Gene name Gene
annotation
Fold
change
Functional
category
complement component 9 C9 9.3 Hemostasis
ceruloplasmin (ferroxidase) CP 5.4 Metal binding
lipopolysaccharide binding
protein
LBP 2.3 Immune response
alpha-2-HS-glycoprotein,
fetuin A
AHSG 2.1 Inﬂammation
complement component 1,
s subcomponent
C1S 2.0 Immune response
amyloid P component,
serum
APCS 2.0 Inﬂammation
inter-alpha-trypsin inhi-
bitor heavy chain 2
ITIH2 2.0 Proteolysis/inhibi-
tion/inﬂammation
coagulation factor II
(thrombin)
F2 1.8 Hemostasis
complement component 2 C2 1.8 Immune response
alpha-2-macroglobulin A2M 1.8 Hemostasis
complement factor B CFB 1.6 Immune response
apolipoprotein H APOH 1.6 Hemostasis
haptoglobin HP 1.4 Inﬂammation
serum amyloid A2, A4 SAA1, SAA2,
SAA4
1.4 Lipid metabolism
and transport
Microarray data from primary human hepatocytes treated with 30 mM RVX-208 for 48 h. Fold change versus DMSO treated cells
is indicated.
S. Wasiak et al. / Data in Brief 8 (2016) 1280–1288 1285(Austin, TX) using the Affymetrix human U133 plus 2.4 Array. Gene expression changes were cal-
culated as a fold change relative to DMSO treated samples. Genes with known roles in atherosclerosis,
thrombosis or inﬂammation (based on published literature) and whose expression changed in
response to RVX-208 treatment (p-valueo0.05, Student's t-test) were compiled into pro-atherogenic
and anti-atherogenic categories.
S. Wasiak et al. / Data in Brief 8 (2016) 1280–128812862.5. Gene expression microarray from primary human hepatocytes
Primary human hepatocytes (CellzDirect/Life Technologies) were plated in 24 well format at
500,000 cells/well, then overlaid with Matrigel™ as recommended by the supplier. Cells were treated
with 0.1% DMSO or 30 mM RVX-208 for 48 h. Total RNA was extracted with the mirVana™ kit
(Ambion) and sent to Asuragen Inc. (Austin, TX) for microarray analysis using Affymetrix Human
Genome U133 Plus 2.0 Array. Gene expression changes were calculated as a fold change relative to
DMSO treated cells. Genes encoding acute phase response proteins associated with HDL (based on
http://homepages.uc.edu/davidswm/HDLproteome.html) and whose expression changed in
response to RVX-208 treatment (p-valueo0.05, Student's t-test) were compiled.Transparency document. supporting material
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